NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. The company has a strategic alliance with Pharmaceutical Product Development Inc. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone239-768-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$276.74 million
Profitability
Miscellaneous
Employees1,030
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable
NeoGenomics (NASDAQ:NEO) Frequently Asked Questions
What is NeoGenomics' stock symbol?
NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
How were NeoGenomics' earnings last quarter?
NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings data on Tuesday, February, 19th. The medical research company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The medical research company had revenue of $76.50 million for the quarter, compared to the consensus estimate of $71.29 million. NeoGenomics had a return on equity of 2.25% and a net margin of 0.95%. NeoGenomics's quarterly revenue was up 24.6% on a year-over-year basis. During the same period last year, the business posted $0.05 EPS. View NeoGenomics' Earnings History.
When is NeoGenomics' next earnings date?
What guidance has NeoGenomics issued on next quarter's earnings?
NeoGenomics issued an update on its FY 2019 earnings guidance on Tuesday, February, 19th. The company provided earnings per share guidance of $0.23-0.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.22. The company issued revenue guidance of $379-395 million, compared to the consensus revenue estimate of $385.69 million.
What price target have analysts set for NEO?
10 brokers have issued 12-month target prices for NeoGenomics' shares. Their forecasts range from $14.00 to $24.00. On average, they anticipate NeoGenomics' share price to reach $18.50 in the next twelve months. This suggests that the stock has a possible downside of 4.2%. View Analyst Price Targets for NeoGenomics.
What is the consensus analysts' recommendation for NeoGenomics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.
What are Wall Street analysts saying about NeoGenomics stock?
Here are some recent quotes from research analysts about NeoGenomics stock:
- 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (3/5/2019)
- 2. BTIG Research analysts commented, "Raising Our PT Earlier this week, we hosted investor meetings with Chairman and CEO Bill Bonello. The general tone was upbeat with majority of the discussions focused on the oncology market opportunity, competitive landscape given recent M&A and use of cash. We felt the overarching theme was the breadth of NEO’s testing capabilities being a competitive differentiator particularly on the clinical trial side. The recently announced agreement with PPD (Private) to be the chief oncology provider would be upside to our current estimates. We are increasing our target EV/sales multiple and PT to $15 (from $11) on increased confidence in Pharma Services, and continued market share capture of clinical testing. Additionally, as NEO moves upstream into higher-end testing, we feel its multiple should more closely match those of specialty cancer testing peers." (6/21/2018)
Has NeoGenomics been receiving favorable news coverage?
Press coverage about NEO stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. NeoGenomics earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of NeoGenomics' key competitors?
Some companies that are related to NeoGenomics include SAGE Therapeutics (SAGE), Exelixis (EXEL), WILLIAM DEMANT/ADR (WILYY), BIO-TECHNE (TECH), Eurofins Scientific (ERFSF), NMC HEALTH PLC/ADR (NMHLY), Recordati (RCDTF), Loxo Oncology (LOXO), Icon (ICLR), Marina Biotech (MRNA), Carl Zeiss Meditec (AFX), Masimo (MASI), Hill-Rom (HRC), Charles River Laboratories Intl. (CRL) and PRA Health Sciences (PRAH).
What other stocks do shareholders of NeoGenomics own?
Who are NeoGenomics' key executives?
NeoGenomics' management team includes the folowing people:
- Mr. Douglas M. VanOort, Chairman & CEO (Age 64)
- Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57)
- Mr. Robert J. Shovlin, Pres of Clinical Services Division (Age 48)
- Dr. Steven G. Brodie, VP of Worldwide Pharma Services Operations (Age 58)
- Ms. Sharon A. Virag, Chief Financial Officer (Age 52)
Who are NeoGenomics' major shareholders?
NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.91%), Brown Advisory Inc. (2.61%), Eagle Asset Management Inc. (2.43%), Emerald Advisers LLC (2.04%), Emerald Mutual Fund Advisers Trust (1.96%) and Granite Investment Partners LLC (1.65%). Company insiders that own NeoGenomics stock include Alison L Hannah, Electric Co General, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.
Which major investors are selling NeoGenomics stock?
NEO stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Falcon Point Capital LLC, Gabelli Funds LLC, Granite Investment Partners LLC, Victory Capital Management Inc., Bank of New York Mellon Corp, Cowen Prime Services LLC and 1492 Capital Management LLC. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven A Ross and Steven C Jones. View Insider Buying and Selling for NeoGenomics.
Which major investors are buying NeoGenomics stock?
NEO stock was acquired by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Millennium Management LLC, BlackRock Inc., Castleark Management LLC, American Century Companies Inc., Jane Street Group LLC, D. E. Shaw & Co. Inc. and Emerald Mutual Fund Advisers Trust. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah and Kevin C Johnson. View Insider Buying and Selling for NeoGenomics.
How do I buy shares of NeoGenomics?
Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeoGenomics' stock price today?
One share of NEO stock can currently be purchased for approximately $19.32.
How big of a company is NeoGenomics?
NeoGenomics has a market capitalization of $1.83 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,030 workers across the globe.
What is NeoGenomics' official website?
How can I contact NeoGenomics?
NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]
MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
